Recently, another structural study also revealed increased thickness in the right dlPFC and right parietal cortex in SAD patients. There is a lack of studies on how the coexistence of schizophrenia and OTX015 anxiety affects brain structure in contrast to each condition by itself. Determining the neuroanatomical substrate underpinning the comorbidity of schizophrenia and anxiety should help to improve diagnostics and management of schizophrenia. To this end, we use voxel-based morphometry on a sample including patients with schizophrenia, schizophrenia with specific ADs, patients with PD and normal controls. Our aim is to determine shared-volume alterations among schizophrenia and specific ADs. Specifically, we are interested in GMV differences in patients with schizophrenia and co-occurring PD and/or SP. Additionally, we examined whether changes in GMV are related to schizophrenic and anxiety symptom severity. Patients were recruited from the Institut de Neuropsiquiatria i Addiccions del Parc de Salut Mar, in Barcelona, Spain. This procedure involved a comprehensive assessment of the medical and Cabozantinib psychiatric history of the patients and a structured interview in order to determine whether they fit the inclusion criteria. Diagnosis was performed during a stabilized period and performed by clinical investigators based on the DSM-IV criteria and the Structured Clinical Interview for DSM-IV. According to these criteria, patients were placed in: the SCZ group when exclusively fulfilling schizophrenia criteria; the SCZ/ANX group when fulfilling schizophrenia and any diagnosis of anxiety : and into the ANX group when fulfilling diagnostic criteria for PD with or without AG and any type of phobia. Patients with comorbidity for DSM-IV axis I or axis II disorders were not included, with the exception of SCZ/ANX patients. It is important mention that, for those subjects medicated with antipsychotics at the time of the scan, doses were converted into chlorpromazine-equivalents, as reported in Table 1. Specifically, 35 of the diagnosed schizophrenic patients were treated with typical antipsychotic medication and two were treated with atypical antipsychotic medication. Regarding the panic and social phobic samples, one patient was taking Vandral and eight were treated with benzodiazepine and selective serotonin reuptake inhibitor anti-depressive medication. Sociodemographic and clinical data were analyzed with SPSS 21. A non-parametric test, Kruskall-Wallis, was used to test for differences between the studied groups, given that our sample did not show a normal distribution. The results of the sociodemographic and clinical data are shown in Table 1, as well as the statistics of the performed distribution test.